-
-
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
-Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022…
-
Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally
-Ferring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees…
-
Ferring Announces New Collaboration for Development of Olamkicept
-Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
-New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.
-
Panicked and overwhelmed: NEW study reveals the emotional and psychological impact of infertility
-New research published in Reproductive Biomedicine, has found that 60% of people believe that the diagnosis and treatment of infertility has impacted their mental health. This impact on mental health has been found to increase with treatment duration and…
-
Gender, health and racial inequalities to be tackled in flagship Ferring grant programme
-Forensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals…
PRESS RELEASE 2022
PRESS RELEASE 2022